Published in Br J Cancer on November 22, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Cancer statistics in China, 2015. CA Cancer J Clin (2016) 12.92
DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem (2001) 12.53
Scleroderma. N Engl J Med (2009) 6.50
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol (2010) 5.61
Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol (2004) 5.31
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
Disparities in cancer diagnosis and survival. Cancer (2001) 2.81
Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature (2007) 2.77
Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer (2001) 2.69
Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2013) 2.46
Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med (2004) 2.29
A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother (2001) 2.18
Tolerance and autoimmunity. N Engl J Med (2001) 1.96
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther (2003) 1.56
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum (2010) 1.54
Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma (1986) 1.30
From ANA to ENA: how to proceed? Autoimmun Rev (2005) 1.18
Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol (2003) 1.11
Serologic autoantibodies as diagnostic cancer biomarkers--a review. Cancer Epidemiol Biomarkers Prev (2013) 1.03
DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res (1999) 1.02
Antigen-specific immunotherapy and cancer vaccines. Int J Cancer (2003) 1.01
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today (2011) 0.95
Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer (2012) 0.92
Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? Autoimmun Rev (2010) 0.91
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules (2015) 0.89
Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res (2008) 0.89
Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol (2001) 0.85
Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev (2016) 0.80
Early detection and monitoring of cancer with the anti-malignin antibody test. Cancer Detect Prev (1994) 0.77
Determination of anti-malignin antibody and malignin in 1,026 cancer patients and controls: relation of antibody to survival. J Med (1982) 0.77
Astrocytin and malignin: two polypeptide fragments (recognins) related to brain tumor. Natl Cancer Inst Monogr (1977) 0.77
In vitro production of the general transformation antibody related to survival in human cancer patients: antimalignin antibody. Cancer Detect Prev (1988) 0.76